• CSS Log In
  • Language
  • Transcriptome Sequencing
  • Eukaryote
  • mRNA Sequencing
  • Non-coding RNA Sequencing
  • Long Non-coding RNA Sequencing
  • Small RNA Sequencing
  • Circular RNA Sequencing
  • Whole Transcriptome Sequencing
  • Isoform Sequencing (Full-length Transcript Sequencing)
  • Prokaryote
  • Prokaryotic RNA Sequencing
  • Metatranscriptome Sequencing
  • Epigenomics
  • Whole Genome Bisulfite Sequencing (Gene Methylation)
  • Reduced Representation Bisulfite Sequencing (RRBS-Gene Methylation)
  • ChIP-Seq
  • RIP-Seq
  • Metagenomics
  • 16S/18S/ITS Amplicon Metagenomic Sequencing
  • Metagenomic Sequencing
  • Pre-made Library Sequencing
  • Pre-made Library Sequencing
  • Clinical Diagnostics
  • CLIA/CAP Whole Exome Sequencing
  • Clinical Panels
  • Genetic Testing
  • Oncology
  • NovoPM™ 2.0
  • NovoFocus™ NSCLC 2.0
  • NovoFocus™ CRC 2.0
  • NovoFocus™ PARPi CDx 1.0
  • NovoFocus™ CR
  • Cancer Immunotherapy Biomarkers
  • Patient's Case Study
  • Service Support
  • Service Workflow
  • Sample Preparation Guide
  • Sample Requirements
  • Quality Management
  • Data Analysis
  • FAQs​​
  • Technology
  • Overview
  • Platform
  • Certification
  • Intelligent Delivery Platform
  • Resources
  • Publications
  • Downloads
  • Webinars
  • About
  • About Us
  • Major Milestones
  • News & Events
  • Careers
  • Contact Us
  • De novo Sequencing
  • Animal & Plant De novo Sequencing
  • Microbial Denovo Sequencing
  • Transcriptome Sequencing

  • Whole Transcriptome Sequencing
  • Isoform Sequencing (Full-length Transcript Sequencing)
  • Prokaryote
  • Prokaryotic RNA Sequencing
  • Metatranscriptome Sequencing
  • Epigenomics

    Metagenomics

    Pre-made Library Sequencing

  • Overview
  • Platform
  • Certification
  • Intelligent Delivery Platform
  • Publications
  • Downloads
  • Webinars
  • About Us
  • Major Milestones
  • News & Events
  • Careers
  • お問い合わせは こちら
    皆様の研究の ニーズに関して お気軽にご相談ください
    Clinical Diagnostics

    Oncology

    Our tests provide valuable insights on clinically relevant alterations in DNA that drive cancer growth, helping to transform targeted therapy, immunotherapy and chemotherapy clinical trials into viable cancer treatment options.

    More Treatment Options with Better Precision For Each Unique Cancer.

    Each cancer is unique and each tumor can vary at the molecular level.

    Our test is a next-generation sequencing (NGS)-based assay that detects genomic alterations relevant for the diagnosis and treatment of solid tumors according to clinical guidelines and medical literature. Our test includes Cancer Immunotherapy Biomarkers: Tumor Mutational Burden (TMB), Blood Tumor Mutational Burden (bTMB), Microsatellite Instability (MSI) and four forms of genomic alterations: single nucleotide variant (SNV), Insertion/Deletion (InDel), copy number variation (CNV) or Fusion. Our reports present the mutations detected in the submitted patient sample and information on approved therapies, clinical trials and other scientific findings.

    What we offer?

    Services NovoPM™ 2.0
    DETAILS NovoFocus™ NSCLC 2.0
    DETAILS NovoFocus™ CR
    DETAILS NovoFocus™ CRC 2.0
    DETAILS NovoFocus™ PARPi CDx 1.0
    DETAILS
    Service Features/ Analysis Results
    For All Solid Tumors
    For Non-Small Cell Lung Cancer
    For Multiple Cancers
    For Colorectal Cancer
    For Breast Cancer Ovarian Cancer and other Solid Tumors
    Evaluates Targeted, Immune and Chemo Therapy
    Evaluates Targeted and Chemo Therapy
    Evaluates Risk Management Measures
    Evaluates Targeted and Chemo Therapy
    Evaluates Targeted and Risk Management Measures
    Predicts Immunotherapy Responses
    Predicts Immunotherapy Responses
    Screens 484 Cancer-related Genes
    Screens 47 NSCLC-related Genes
    Screens 106 hereditary genes
    Screens 50 CRC-related Genes
    Screens BRCA1/2 and HRD-related Genes
    Step 1:
    Send us Patient's Sample
    Step 2:
    Sample Preparation
    Step 3:
    Library preparation & Sequencing
    Step 4:
    Bioinformatics Analysis
    Step 5:
    Actionable report
    Step 1:
    Send us Patient's Sample
    Step 2:
    Sample Preparation
    Step 3:
    Library preparation & Sequencing
    Step 4:
    Bioinformatics Analysis
    Step 5:
    Actionable report

    Frequently asked questions about our diagnostic process

    Precision Medicine is an emerging approach to disease prevention and treatment that takes into account the differences of genetic, environmental, and lifestyle between individuals.

    Precision Medicine is currently the most novel way to treat cancer. The comprehensive genomic profiling (CGP) test can help patients find the mutated genes, and then give the interpretation of the alterations as well as corresponding therapy instructions. Ideally, upon treatment of the therapies suggested, patient’s condition can be most effectively controlled in the shortest time and unnecessary side effects can be avoided, since the medical treatment is specific to the patient himself that considers his genetic mutations.

    Genetic testing can give you and your doctor more information about cancer therapy. This information can help your doctor determine the most appropriate treatment strategy. Since the treatment of cancer could be very complicated, which depends on the type of cancer, the physical condition of the patient, as well as the history of medications, please fully discuss with your physician about the suitable testing product and timing, so as to improve the testing effectiveness.

    Novogene's clinical oncology testing performs multi-gene testing for cancer patients. The testing service is different from the single-gene testing in hospitals, as it can provide complete genetic alteration analysis on genes included in the testing panel.

    We provide genetic mutations with related interpretation, medication information, clinical trials information and related references.

    Results & Reporting

    Information about identified genomic alterations of all types and interpretation of results.

    List of available targeted therapy, immunotherapy and chemotherapy relevant for the genomic alterations and biomarkers identified.

    Clinical trials that the patient may be eligible for and guidance for the physician on identifying additional trials in public databases.

    Early detection provides the opportunity to maximize health outcomes for your high-risk patient groups with patient-tailored screening programs, preventive measeures and proactive treatment.

    Information about identified genomic alterations of all types and interpretation of results.

    List of available targeted therapy, immunotherapy and chemotherapy relevant for the genomic alterations and biomarkers identified.

    Clinical trials that the patient may be eligible for and guidance for the physician on identifying additional trials in public databases.

    Early detection provides the opportunity to maximize health outcomes for your high-risk patient groups with patient-tailored screening programs, preventive measeures and proactive treatment.

    More resources

    Cancer Immunotherapy Biomarkers

    Learn more

    Patient’s Case Study

    Learn more

    More Clinical Diagnostics